THE DEAL, AT A GLANCE
From the announcementRemepy
01What happenedRemepy raised $36M Series D, announced 2026-08-12From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Why it mattersRemepy is using a $36M Series D to develop hybrid drugs that combine traditional medications with therapeutic software.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Remepy · Financing Record
Explore source-linked visual explanations for Remepy. Unsupported claims are withheld while source review continues.
Record 10138 · Recorded date: 2026-08-12
What it does
Regulated like medicine, adaptive like software, and reimbursed like pharma, Remepy’s Hybrid Drugs are designed to deliver better outcomes, introducing a new growth model for the industry.
Source: remepy.com ↗